SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
New Jersey Natural Gas submitted filings providing 8.9% bill savings ($158 annually per residential customer) for winter 2026-2027 while seeking base rate increases of 12.7% to rec…
Spectral AI announced FDA De Novo Classification for its DeepView System for burn wound assessment, authorizing commercial distribution in the U.S. The company also secured $31.7 m…
Oruka Therapeutics and Paragon Therapeutics executed a first amendment to their IL-23 license agreement dated May 29, 2026, expanding the Field definition from inflammatory bowel d…
Exicure received a Nasdaq delinquency notice for late filing of its Q1 2026 Form 10-Q, attributed to changes in financial reporting personnel. The company filed the report on May 2…
Gemaxel Inc submitted its certificate of incorporation as an exhibit to an 8-K filing, establishing the corporation's legal name and basic incorporation details. This is a standard…
Flutter Entertainment plc disclosed its total voting rights, confirming 173,400,475 ordinary shares in issue with €0.09 nominal value each. This disclosure is required under UK FCA…
CPS Technologies amended its Certificate of Incorporation to increase authorized Common Stock from an unspecified amount to 25 million shares at $0.01 par value, approved by stockh…
BTCS Inc. reduced the quorum requirement for stockholder meetings from an unspecified prior level to one-third of voting power through a bylaw amendment approved May 29, 2026. This…
CECO Environmental Corp filed amended and restated bylaws covering stockholder meetings, voting procedures, and board governance. The filing reflects standard Delaware corporate go…
Outlook Therapeutics resubmitted its Biologics License Application for ONS-5010/LYTENAVA to the FDA after successfully appealing a Complete Response Letter, with a Class 1 review d…
PwC consented to include its audit report dated March 12, 2026 in GoPro's Form S-8 registration statements, with updated going concern opinions as of June 1, 2026. The going concer…
Turn Therapeutics announced interim analysis results from its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, showing 92.6% of treated subjects achieved 50% eczema…
NextCure announced 55% objective response rate for SIM0505 in gynecologic cancers at ASCO 2026, with favorable safety in heavily pretreated patients. The data supports continued do…
zSpace amended its Series P Convertible Preferred Stock certificate, reducing authorized shares from 5 million to 2 million and lowering the conversion price to $1.00 per share wit…
Jade Biosciences held a conference call on June 1, 2026 to discuss interim Phase 1 data for JADE101, a clinical-stage therapeutic candidate. The company plans to advance to Phase 2…
FirstEnergy Corp released a Spring 2026 investor update focusing on forward-looking guidance while managing ongoing government investigations and a Deferred Prosecution Agreement. …
NusaTrip Incorporated received a delinquency notification from Nasdaq on May 27, 2026 for failing to timely file its 2025 Form 10-K and Q1 2026 Form 10-Q. The company has 60 days t…
Elite Pharmaceuticals submitted an Abbreviated New Drug Application to the FDA for a generic anticoagulant product in a $26 billion market with no current generic competition. Appr…
Summit Therapeutics presented Phase II data for ivonescimab combined with chemotherapy in first-line metastatic colorectal cancer, achieving a 70.8% objective response rate with ma…
Rising Dragon Acquisition Corp. filed its Second Amended and Restated Memorandum and Articles of Association, effective May 28, 2026, as a Cayman Islands company. The filing establ…